Publication | Open Access

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

RheumatologySubcutaneous IscalimabWeek 24Phase 2BClinical TrialsDermatologySclerodermaMedicineRheumatoid Arthritis